The efficacy threshold and costs may increase exponentially for HCV developers if the trial design changes I suggest in #msg-106203900 come to bear. Under this scenario the ENTA 2-drug combo may skirt this requirement since Phase-2b testing has already begun. If you don't understand this threat, you are exposing yourself to undue risk investing in early-stage developers.